Edition:
United States

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

15.36USD
3:24pm EDT
Change (% chg)

$-0.45 (-2.85%)
Prev Close
$15.81
Open
$15.76
Day's High
$15.90
Day's Low
$15.16
Volume
102,094
Avg. Vol
228,340
52-wk High
$32.39
52-wk Low
$12.85

DVAX.OQ

Chart for DVAX.OQ

About

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company's lead vaccine product candidate is HEPLISAV-B, an... (more)

Overall

Beta: 2.52
Market Cap(Mil.): $608.62
Shares Outstanding(Mil.): 38.50
Dividend: --
Yield (%): --

Financials

  DVAX.OQ Industry Sector
P/E (TTM): -- 42.74 36.62
EPS (TTM): -2.84 -- --
ROI: -83.80 -9.63 14.52
ROE: -89.85 -9.94 15.68

BRIEF-Dynavax Q1 loss per share $0.70

* Q1 earnings per share view $-0.63, revenue view $1.1 million -- Thomson Reuters I/B/E/S

May 09 2016

BRIEF-Dynavax Technologies receives notification of PDUFA extension for Heplisav-B

* Says Dynavax receives notification of PDUFA extension for Heplisav-B to Dec. 15, 2016

Apr 27 2016

BRIEF-Dynavax presents encouraging data from clinical trial of immuno-oncology product candidate, SD-101

* Dynavax presents encouraging data from clinical trial of immuno-oncology product candidate, SD-101 Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +1 646 223 8780)

Apr 18 2016

BRIEF-Dynavax presents pivotal phase 3 data showing HEPLISAV-B provides significantly higher protection against Hepatitis B than ENGERIX-B(R)

* Dynavax presents pivotal phase 3 data showing heplisav-b(tm) provides significantly higher protection against hepatitis b than engerix-b(r)

Apr 18 2016

BRIEF-Dynavax announces FDA acceptance for review of Biologics License Application and PDUFA action date for HEPLISAV-b(tm)

* Dynavax announces FDA acceptance for review of Biologics License Application and PDUFA action date for HEPLISAV-b(tm) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Mar 30 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.